Zamzam S. Hashami-Al

Muscat, MA, Oman

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

When Constriction Is Not Just the Pericardium: Extrinsic Cardiac Encasement by Thymic Squamous Cell Carcinoma.

When Constriction Is Not Just the Pericardium: Extrinsic Cardiac Encasement by Thymic Squamous Cell Carcinoma.

Journal: Cureus

Published: March 22, 2026

The clinical utility of endobronchial ultrasound-guided transbronchial needle aspiration: A single-center experience from the Middle East.

The clinical utility of endobronchial ultrasound-guided transbronchial needle aspiration: A single-center experience from the Middle East.

Journal: Annals of thoracic medicine

Published: December 02, 2025

ECTOPIC THYROID PRESENTING AS MEDIASTINAL MASS.

ECTOPIC THYROID PRESENTING AS MEDIASTINAL MASS.

Journal: Acta endocrinologica (Bucharest, Romania : 2005)

Published: October 10, 2025

When cancer reaches the heart: a case series on rare myocardial and endocardial metastases from squamous cell carcinoma.

When cancer reaches the heart: a case series on rare myocardial and endocardial metastases from squamous cell carcinoma.

Journal: Archive of clinical cases

Published: March 20, 2025

Silent Invader: Cardiac Metastasis From Buccal Squamous Cell Carcinoma.

Silent Invader: Cardiac Metastasis From Buccal Squamous Cell Carcinoma.

Journal: Cureus

Published: July 17, 2024

Tracheal necrosis after sandwich immunotherapy and stereotactic body radiotherapy for lung cancer.

Tracheal necrosis after sandwich immunotherapy and stereotactic body radiotherapy for lung cancer.

Journal: African journal of thoracic and critical care medicine

Published: October 18, 2023

The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman.

The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman.

Journal: Cureus

Published: October 15, 2023

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.

Journal: Current oncology (Toronto, Ont.)

Published: April 02, 2023

Adenocarcinoma of lung presenting as diffuse interstitial lung disease.

Adenocarcinoma of lung presenting as diffuse interstitial lung disease.

Journal: The Lancet. Oncology

Published: March 30, 2023

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.

Journal: BMC cancer

Published: November 24, 2022

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.

Journal: Current oncology (Toronto, Ont.)

Published: October 26, 2022

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.

Journal: Current oncology (Toronto, Ont.)

Published: October 04, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026